These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. C-reactive protein is elevated in schizophrenia. Dickerson F; Stallings C; Origoni A; Vaughan C; Khushalani S; Yang S; Yolken R Schizophr Res; 2013 Jan; 143(1):198-202. PubMed ID: 23218564 [TBL] [Abstract][Full Text] [Related]
23. Infection and inflammation in schizophrenia and bipolar disorder. Tanaka T; Matsuda T; Hayes LN; Yang S; Rodriguez K; Severance EG; Yolken RH; Sawa A; Eaton WW Neurosci Res; 2017 Feb; 115():59-63. PubMed ID: 27856235 [TBL] [Abstract][Full Text] [Related]
24. The influence of latent viral infection on rate of cognitive decline over 4 years. Aiello AE; Haan M; Blythe L; Moore K; Gonzalez JM; Jagust W J Am Geriatr Soc; 2006 Jul; 54(7):1046-54. PubMed ID: 16866674 [TBL] [Abstract][Full Text] [Related]
25. The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis. Johnsen E; Fathian F; Kroken RA; Steen VM; Jørgensen HA; Gjestad R; Løberg EM BMC Psychiatry; 2016 Mar; 16():60. PubMed ID: 26973142 [TBL] [Abstract][Full Text] [Related]
26. C-reactive protein mediates the effect of apolipoprotein E on cytomegalovirus infection. Aiello AE; Nguyen HO; Haan MN J Infect Dis; 2008 Jan; 197(1):34-41. PubMed ID: 18171282 [TBL] [Abstract][Full Text] [Related]
27. Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study. Breier A; Buchanan RW; D'Souza D; Nuechterlein K; Marder S; Dunn W; Preskorn S; Macaluso M; Wurfel B; Maguire G; Kakar R; Highum D; Hoffmeyer D; Coskinas E; Litman R; Vohs JL; Radnovich A; Francis MM; Metzler E; Visco A; Mehdiyoun N; Yang Z; Zhang Y; Yolken RH; Dickerson FB Schizophr Res; 2019 Apr; 206():291-299. PubMed ID: 30478008 [TBL] [Abstract][Full Text] [Related]
28. Altered interleukin-18 levels are associated with cognitive impairment in chronic schizophrenia. Wu JQ; Chen DC; Tan YL; Tan SP; Xiu MH; Wang ZR; Yang FD; Soares JC; Zhang XY J Psychiatr Res; 2016 May; 76():9-15. PubMed ID: 26866662 [TBL] [Abstract][Full Text] [Related]
29. Cognition impairment in schizophrenia patients with tardive dyskinesia: association with plasma superoxide dismutase activity. Wu JQ; Chen DC; Tan YL; Tan SP; Wang ZR; Xiu MH; Yang FD; Zhang XY Schizophr Res; 2014 Jan; 152(1):210-6. PubMed ID: 24325977 [TBL] [Abstract][Full Text] [Related]
30. Exposure to herpes simplex virus type 1 and cognitive impairments in individuals with schizophrenia. Prasad KM; Watson AM; Dickerson FB; Yolken RH; Nimgaonkar VL Schizophr Bull; 2012 Nov; 38(6):1137-48. PubMed ID: 22490995 [TBL] [Abstract][Full Text] [Related]
31. Antibodies to Toxoplasma gondii and cognitive functioning in schizophrenia, bipolar disorder, and nonpsychiatric controls. Dickerson F; Stallings C; Origoni A; Katsafanas E; Schweinfurth L; Savage C; Khushalani S; Yolken R J Nerv Ment Dis; 2014 Aug; 202(8):589-93. PubMed ID: 25010110 [TBL] [Abstract][Full Text] [Related]
32. Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Fan X; Pristach C; Liu EY; Freudenreich O; Henderson DC; Goff DC Psychiatry Res; 2007 Jan; 149(1-3):267-71. PubMed ID: 17112596 [TBL] [Abstract][Full Text] [Related]
33. Persistent infection by HSV-1 is associated with changes in functional architecture of iPSC-derived neurons and brain activation patterns underlying working memory performance. D'Aiuto L; Prasad KM; Upton CH; Viggiano L; Milosevic J; Raimondi G; McClain L; Chowdari K; Tischfield J; Sheldon M; Moore JC; Yolken RH; Kinchington PR; Nimgaonkar VL Schizophr Bull; 2015 Jan; 41(1):123-32. PubMed ID: 24622295 [TBL] [Abstract][Full Text] [Related]
34. Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar patients and its impact on psychosocial functioning: preliminary results. Dittmann S; Seemüller F; Schwarz MJ; Kleindienst N; Stampfer R; Zach J; Born C; Bernhard B; Fast K; Grunze H; Engel RR; Severus E Bipolar Disord; 2007; 9(1-2):63-70. PubMed ID: 17391351 [TBL] [Abstract][Full Text] [Related]
35. HSV-1 and HSV-2 seroprevalence in the united states among asymptomatic women unaware of any herpes simplex virus infection (Herpevac Trial for Women). Schulte JM; Bellamy AR; Hook EW; Bernstein DI; Levin MJ; Leone PA; Sokol-Anderson ML; Ewell MG; Wolff PA; Heineman TC; Belshe RB South Med J; 2014 Feb; 107(2):79-84. PubMed ID: 24926671 [TBL] [Abstract][Full Text] [Related]
36. Persistent infection with neurotropic herpes viruses and cognitive impairment. Watson AM; Prasad KM; Klei L; Wood JA; Yolken RH; Gur RC; Bradford LD; Calkins ME; Richard J; Edwards N; Savage RM; Allen TB; Kwentus J; McEvoy JP; Santos AB; Wiener HW; Go RC; Perry RT; Nasrallah HA; Gur RE; Devlin B; Nimgaonkar VL Psychol Med; 2013 May; 43(5):1023-31. PubMed ID: 22975221 [TBL] [Abstract][Full Text] [Related]
37. Transferred herpes simplex virus immunity after stem-cell transplantation: clinical implications. Nichols WG; Boeckh M; Carter RA; Wald A; Corey L J Infect Dis; 2003 Mar; 187(5):801-8. PubMed ID: 12599054 [TBL] [Abstract][Full Text] [Related]
38. Seropositivity of neurotropic infectious agents in first-episode schizophrenia patients and the relationship with positive and negative symptoms. Bolu A; Oznur T; Tok D; Balikci A; Sener K; Celik C; Gulsun M Psychiatr Danub; 2016 Jun; 28(2):132-8. PubMed ID: 27287787 [TBL] [Abstract][Full Text] [Related]